These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

671 related articles for article (PubMed ID: 33135381)

  • 1. Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019.
    Knopman DS; Jones DT; Greicius MD
    Alzheimers Dement; 2021 Apr; 17(4):696-701. PubMed ID: 33135381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aducanumab for Alzheimer's Disease: Summarized Data From EMERGE, ENGAGE, and PRIME Studies.
    Yuksel JM; Noviasky J; Britton S
    Sr Care Pharm; 2022 Aug; 37(8):329-334. PubMed ID: 35879846
    [No Abstract]   [Full Text] [Related]  

  • 3. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease.
    Salloway S; Chalkias S; Barkhof F; Burkett P; Barakos J; Purcell D; Suhy J; Forrestal F; Tian Y; Umans K; Wang G; Singhal P; Budd Haeberlein S; Smirnakis K
    JAMA Neurol; 2022 Jan; 79(1):13-21. PubMed ID: 34807243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.
    Budd Haeberlein S; Aisen PS; Barkhof F; Chalkias S; Chen T; Cohen S; Dent G; Hansson O; Harrison K; von Hehn C; Iwatsubo T; Mallinckrodt C; Mummery CJ; Muralidharan KK; Nestorov I; Nisenbaum L; Rajagovindan R; Skordos L; Tian Y; van Dyck CH; Vellas B; Wu S; Zhu Y; Sandrock A
    J Prev Alzheimers Dis; 2022; 9(2):197-210. PubMed ID: 35542991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab.
    Mallinckrodt C; Tian Y; Aisen PS; Barkhof F; Cohen S; Dent G; Hansson O; Harrison K; Iwatsubo T; Mummery CJ; Muralidharan KK; Nestorov I; Nisenbaum L; Rajagovindan R; von Hehn C; van Dyck CH; Vellas B; Wu S; Zhu Y; Sandrock A; Chen T; Budd Haeberlein S
    J Prev Alzheimers Dis; 2023; 10(2):171-177. PubMed ID: 36946443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Aducanumab in the Treatment of Alzheimer's Disease: Challenges and Opportunities.
    Vaz M; Silva V; Monteiro C; Silvestre S
    Clin Interv Aging; 2022; 17():797-810. PubMed ID: 35611326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Questions EMERGE as Biogen claims aducanumab turnaround.
    Howard R; Liu KY
    Nat Rev Neurol; 2020 Feb; 16(2):63-64. PubMed ID: 31784690
    [No Abstract]   [Full Text] [Related]  

  • 8. Aducanumab-Hope or Disappointment for Alzheimer's Disease.
    Wojtunik-Kulesza K; Rudkowska M; Orzeł-Sajdłowska A
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ENGAGE and EMERGE: Truth and consequences?
    Kuller LH; Lopez OL
    Alzheimers Dement; 2021 Apr; 17(4):692-695. PubMed ID: 33656288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer's Disease: Need for Prognostic Biomarkers?
    Piazza F; Winblad B
    J Alzheimers Dis; 2016 Mar; 52(2):417-20. PubMed ID: 27031492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aducanumab: First Approval.
    Dhillon S
    Drugs; 2021 Aug; 81(12):1437-1443. PubMed ID: 34324167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aducanumab for the treatment of Alzheimer's disease: a systematic review.
    Rahman A; Hossen MA; Chowdhury MFI; Bari S; Tamanna N; Sultana SS; Haque SN; Al Masud A; Saif-Ur-Rahman KM
    Psychogeriatrics; 2023 May; 23(3):512-522. PubMed ID: 36775284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.
    Sevigny J; Chiao P; Bussière T; Weinreb PH; Williams L; Maier M; Dunstan R; Salloway S; Chen T; Ling Y; O'Gorman J; Qian F; Arastu M; Li M; Chollate S; Brennan MS; Quintero-Monzon O; Scannevin RH; Arnold HM; Engber T; Rhodes K; Ferrero J; Hang Y; Mikulskis A; Grimm J; Hock C; Nitsch RM; Sandrock A
    Nature; 2016 Sep; 537(7618):50-6. PubMed ID: 27582220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease.
    Budd Haeberlein S; O'Gorman J; Chiao P; Bussière T; von Rosenstiel P; Tian Y; Zhu Y; von Hehn C; Gheuens S; Skordos L; Chen T; Sandrock A
    J Prev Alzheimers Dis; 2017; 4(4):255-263. PubMed ID: 29181491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Bayesian perspective on Biogen's aducanumab trial.
    Temp AGM; Ly A; van Doorn J; Wagenmakers EJ; Tang Y; Lutz MW; Teipel S
    Alzheimers Dement; 2022 Nov; 18(11):2341-2351. PubMed ID: 35235700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aducanumab: Appropriate Use Recommendations.
    Cummings J; Aisen P; Apostolova LG; Atri A; Salloway S; Weiner M
    J Prev Alzheimers Dis; 2021; 8(4):398-410. PubMed ID: 34585212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice.
    Kastanenka KV; Bussiere T; Shakerdge N; Qian F; Weinreb PH; Rhodes K; Bacskai BJ
    J Neurosci; 2016 Dec; 36(50):12549-12558. PubMed ID: 27810931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Making the Case for the Accelerated Withdrawal of Aducanumab.
    Whitehouse PJ; Saini V
    J Alzheimers Dis; 2022; 87(3):999-1001. PubMed ID: 35491796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Public opinion regarding U.S. Food and Drug Administration approval of aducanumab and potential policy responses: A nationally representative survey.
    DiStefano MJ; Alexander GC; Polsky D; Anderson GF
    J Am Geriatr Soc; 2022 Jun; 70(6):1685-1694. PubMed ID: 35129210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aducanumab for Alzheimer disease: the amyloid hypothesis moves from bench to bedside.
    Musiek ES; Gomez-Isla T; Holtzman DM
    J Clin Invest; 2021 Oct; 131(20):. PubMed ID: 34651585
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 34.